US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Latest News about OKYO Pharma

Recent news which mentions OKYO Pharma

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
Tickers ALPMF ISEE OKYO VTRS
Tags XNAS:OKYO OKYO Pharma
From TheNewswire.com - RSS (Media)
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
Tickers ALPMF ISEE OKYO VTRS
Tags Partner Content Health Care Markets
From Benzinga
Phase 2 Trials Begin For Promising New Dry Eye Disease Treatment From OKYO Pharma
Tickers OKYO
Tags Benzinga All Access OKYO Pharma Interview
From Benzinga
OKYO Pharma Reports First Patient Visit For Phase 2 Trial Of OK-101, To Fulfill One Of The Two Phase 3 Studies Required For FDA Approval If Successful
Tickers OKYO
Tags Market News News OKYO Pharma
From Benzinga
OKYO Pharma Activates First Clinical Trial Site For Phase 2 Study Of OK-101 To Treat Dry Eye Disease
Tickers OKYO
Tags Penny Stocks General OKYO
From Benzinga
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Tickers ALDX OCUL OKYO TARS
Tags Private Placement OKYO Penny Stocks
From Benzinga
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
Tickers ALDX OCUL OKYO TARS
Tags XNAS:OKYO OKYO Pharma
From TheNewswire.com - RSS (Media)
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
Tickers ALDX OCUL OKYO TARS
Tags News Market News OKYO Pharma
From Benzinga
OKYO Pharma's Trial Treating Subjects With DED Gets Listed On ClinicalTrials.gov
Tickers OKYO
Tags Penny Stocks General Benzinga
From Benzinga
OKYO Pharma CEO Gary Jacob Discusses The Company's Future Plans
Tags Interview OKYO Pharma Market News
From Benzinga
OKYO Pharma's Drug OK-101 Clears Customs in the US; To Be Used In Phase 2, First-In-Human, Clinical Trial For Patients With Dry Eye Disease
Tickers OKYO
Tags Benzinga Biotech OKYO
From Benzinga
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution
Tickers ALDX OKYO TARS
Tags XNAS:OKYO OKYO Pharma
From TheNewswire.com - RSS (Media)
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough
Tickers ALDX OKYO TARS
Tags Biotech Benzinga ALDX
From Benzinga